AQST: March 2027 FDA review supports outlook despite lower Q3 revenue and losses.document-source7document-source38

What happened

AQST reported that third-quarter revenue fell 41% year over year as revenue from supplying Suboxone declined. Revenue for the first nine months rose 14%, including a one-time $5.0 million royalty. The FDA review of Anaphylm is scheduled for March 2027, and quarter-end cash was $90.3 million.

Confirmed

Global impact / market context

Lower quarterly revenue and reported losses point to pressure on current business performance, while the scheduled Anaphylm review is a potential future product milestone. The $90.3 million cash balance is relevant to how the company funds operations while awaiting that review.

Analyst inference

The figures show different trends over different periods: third-quarter revenue declined, but nine-month revenue increased, partly because of a one-time royalty that may not recur. For investors, the March 2027 review date places a key regulatory event ahead rather than confirming a product launch.

Analyst inference

What to watch

1. Watch for later updates on the FDA review schedule for Anaphylm; the article gives March 2027 as the expected review timing, not an approval decision. Confirmed
2. Track whether Suboxone supply revenue continues to decline, since further weakness could weigh on quarterly revenue and make the nine-month growth figure less representative. Analyst inference
3. Compare future cash balances and operating results with the reported $90.3 million quarter-end cash to assess the resources available before the Anaphylm review. Analyst inference

Evidence

• Original source link unavailable